Skip to main content
SpringerLink
Log in

Successful treatment of atopic dermatitis by switching from upadacitinib to abrocitinib: a case report

  • Correspondence
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kamata M, Tada Y. Optimal use of Jak inhibitors and biologies for atopic dermatitis on the basis of the current evidence. JID Innov 2023; 3: 100195.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bieber T, Palier AS, Kabashima K, et al. Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. J Eur Acad Dermatol Venereal 2022; 36: 1432–49.

    Article  CAS  Google Scholar 

  3. Blauvelt A, Silverberg Jl, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol 2022; 86: 104–12.

    Article  CAS  PubMed  Google Scholar 

  4. Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol 2022; 158: 404–13.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Eichner A, Wohlrab J. Pharmacology of inhibitors of Janus kinases - Part 1: pharmacokinetics. J Dtsch Dermatol Ges 2022; 20: 1485–99.

    PubMed  Google Scholar 

  6. Eichner A, Wohlrab J. Pharmacology of inhibitors of Janus kinases - Part 2: pharmacodynamics. J Dtsch Dermatol Ges 2022; 20: 1621–31.

    PubMed  Google Scholar 

  7. Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK 1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2018; 28: 23.

    Article  Google Scholar 

  8. Bauman JN, Doran AC, King-Ahmad A, et al. The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective janus kinase inhibitor, in humans. Drug Metab Dispos 2022; 50: 1106–18.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Funding sources none.

Author information

Authors and Affiliations

  1. Department of Dermatology, Far Eastern Memorial Hospital, New Taipei, Taiwan

    Ya-Chu Tsai

  2. Minghsin University of Science and Technology, Hsinchu, Taiwan

    Ya-Chu Tsai

  3. Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

    Tsen-Fang Tsai

Authors
  1. Ya-Chu Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsen-Fang Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ya-Chu Tsai or Tsen-Fang Tsai.

Ethics declarations

Conflicts of interest Dr. Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for Abb Vie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, EliLilly, Galderma, GSK-Stiefel, Janssen-Cilag, Leo-Pharma, Merck, Novartis, Pfizer Inc., and UCB Pharma. Dr. Ya-Chu Tsai has delivered speeches held by Abb Vie, Boehringer Ingelheim, EliLilly, Janssen-Cilag, Leo-Pharma, Novartis, Pfizer Inc., Sanofi, Viatris.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsai, YC., Tsai, TF. Successful treatment of atopic dermatitis by switching from upadacitinib to abrocitinib: a case report. Eur J Dermatol 33, 699–701 (2023). https://doi.org/10.1684/ejd.2023.4581

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2023.4581

Search

Navigation